Compare Ginkgo Bioworks Holdings Inc (DNA) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs General Dynamics Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.1 (market cap $590.53M), while General Dynamics Corporation trades at $368.31 (market cap $99.92B). The key difference: General Dynamics Corporation is far larger — about 169.2× Ginkgo Bioworks Holdings Inc's market cap, and General Dynamics Corporation pays a 1.72% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | GD | |
|---|---|---|
Market Cap | $590.53M | $99.92B |
Sector | Health | Industrials |
52-Week High | $16.14 | $376.88 |
52-Week Low | $5.48 | $297.05 |
Enterprise Value | $627.78M | $106.10B |
Dividend Yield | — | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
General Dynamics (GD) trades at $372.78, down 0.61% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.10 versus $3.67 expected, and maintains solid fundamentals including 8.07% net income margin and 17.97% ROE. Revenue growth continues, reaching $52.55 billion in 2025, with a robust backlog of $130.8 billion highlighting strong demand in naval and defense sectors.
Outlook remains positive driven by defense spending tailwinds and submarine contract momentum, though valuation multiples like P/E of 23.46 suggest limited upside near-term. Risks include execution on large contracts and geopolitical volatility. Analyst consensus is bullish with a $395.83 price target, indicating ~6% potential appreciation from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
